Shin Nippon Biomedical Laboratories (SNBL)
Tokyo · Founded 1957
About Shin Nippon Biomedical Laboratories (SNBL)
Shin Nippon Biomedical Laboratories (SNBL), was founded in Kagoshima as Japan’s first contract research organization in 1957. Since then, SNBL has steadily expanded and innovated to become a global business that works in the pre-clinical research, clinical pharmacology research, pharmacokinetics and analysis, clinical trial, SMO, and other industries. In recent years, they have built strong partnerships based on their corporate philosophy, including with their translational research business partner. SNBL is striving toward globalization and expanded from Japan into North America, Europe, and other parts of Asia. SNBL has over 50 years of experience as a contract research organization. They provide study data about safety and efficacy pharmaceuticals, which is essential to pharmaceutical companies in the drug development process. In addition to their abundant experience, they have established a global group with branches in Japan, the United States, China, Cambodia, and other global sites, with reliability being the key to their success. They work together across SNBL group to quickly and accurately meet the needs of their clients from all around the world, from basic research to late-stage clinical trials, service in all areas of research and development. Their corporate mission is that "They are committed to freeing patients from suffering by supporting drug development and improving medical technologies." This is the cornerstone of everything they do at SNBL Group.
Company Facts
- Founded: 1957
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1,001 – 5,000
- Estimated revenue: $100K – $500K
- Ticker: tyo:2395
- Website: snbl.co.jp
- Phone: +81355655001
Industries & Categories
Biotechnology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/shin-nippon-biomedical-laboratories-snbl-1789164 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.